Lee's Pharmaceutical Holdings Limited

SEHK:950 Voorraadrapport

Marktkapitalisatie: HK$736.0m

Lee's Pharmaceutical Holdings Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lee's Pharmaceutical Holdings.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei11.1%
Inkomstengroein/a
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

None

Laatst bijgewerktn/a

Recente toekomstige groei-updates

Recent updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04
Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07
There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21
Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20
Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

May 21
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Apr 02
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Aug 29
Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Apr 05
Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17
Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22
Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29
What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12
What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Lee's Pharmaceutical Holdings onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

SEHK:950 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (HKD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
6/30/20241,1996314130N/A
3/31/20241,12640-8120N/A
12/31/20231,05317-30110N/A
9/30/20239805N/AN/AN/A
6/30/20231,09639-13370N/A
3/31/20231,16539N/AN/AN/A
12/31/20221,2335170284N/A
9/30/20221,350-119N/AN/AN/A
6/30/20221,331-140103317N/A
3/31/20221,3081,966N/AN/AN/A
12/31/20211,2661,987-160211N/A
9/30/20211,2752,176N/AN/AN/A
6/30/20211,2442,188-65394N/A
3/31/20211,227130N/AN/AN/A
12/31/20201,217129-139219N/A
9/30/20201,199167N/AN/AN/A
6/30/20201,168184-142179N/A
3/31/20201,209118N/AN/AN/A
12/31/20191,21912639400N/A
9/30/20191,185301N/AN/AN/A
6/30/20191,177331-43309N/A
3/31/20191,139395N/AN/AN/A
12/31/20181,13841827321N/A
9/30/20181,126243N/AN/AN/A
6/30/20181,10123345447N/A
3/31/20181,064256N/AN/AN/A
12/31/20171,009233N/A366N/A
9/30/2017981245N/AN/AN/A
6/30/2017955256N/A358N/A
3/31/2017930245N/AN/AN/A
12/31/2016930252N/A395N/A
9/30/2016911259N/AN/AN/A
6/30/2016894247N/A309N/A
3/31/2016917242N/AN/AN/A
12/31/2015922229N/A160N/A
9/30/2015976221N/AN/AN/A
6/30/2015990209N/A140N/A
3/31/2015979191N/AN/AN/A
12/31/2014955193N/A220N/A
9/30/2014874175N/AN/AN/A
6/30/2014805164N/A255N/A
3/31/2014755160N/AN/AN/A
12/31/2013697150N/A179N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if 950's forecast earnings growth is above the savings rate (2.3%).

Winst versus markt: Insufficient data to determine if 950's earnings are forecast to grow faster than the Hong Kong market

Hoge groeiwinsten: Insufficient data to determine if 950's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if 950's revenue is forecast to grow faster than the Hong Kong market.

Hoge groei-inkomsten: Insufficient data to determine if 950's revenue is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if 950's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven